Therefore, the discovery of KMT2A antagonists able to reduce H3K4-me3 expression, and thus to reduce REST levels, could represent a new and additional pharmacological strategy to intervene in the treatment of ALS patients. The gene discussed is REST; the disease is amyotrophic lateral sclerosis.